A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Takeda
Study ID
NCT06088043
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TAK-279 — DRUG
    Specified drug on specified days.
  • Placebo — DRUG
    Specified drug on specified days.
  • Apremilast — DRUG
    Specified drug on specified days.

Study Details

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 61 weeks.

Key Dates

Start date
Nov 6, 2023
Status verified
Oct 2025
Primary completion
Jan 22, 2025
Completion
Oct 22, 2025

Study Design

Enrollment
693 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: TAK-279
  • Placebo Comparator: Placebo
  • Active Comparator: Apremilast

Primary Outcome Measure

Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) with a >=2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo [ Time Frame: Baseline, Week 16 ]

Locations (27)

FacilityCityStateZIPSite coordinators
Saguaro Dermatology Associates, LLC - Probity - PPDSPhoenixArizona85008-3884-
First OC Dermatology - Fountain ValleyFountain ValleyCalifornia92708-3701-
Center for Dermatology Clinical ResearchFremontCalifornia94538-1614-
UCLA University of California Los AngelesLos AngelesCalifornia90024-
UC Davis Dermatology ClinicSacramentoCalifornia95816-3370-
Driven Research LLCCoral GablesFlorida33134-3901-
FXM Clinical Research Ft. Lauderdale, LLCFort LauderdaleFlorida33308-5211-
Direct Helpers Research CenterHialeahFlorida33012-3618-
FXM Clinical Research Miami, LLCMiamiFlorida33175-3582-
Renstar Medical Research -21 NE 1st AveOcalaFlorida34470-6657-
Marietta Dermatology & The Skin Cancer Center - MariettaMariettaGeorgia30060-7902-
Leavitt Clinical Research - 1542 Elk Creek DrIdaho FallsIdaho83404-8322-
Arlington DermatologyRolling MeadowsIllinois60008-3811-
Dawes Fretzin Clinical Research Group-7910 N Shadeland AveIndianapolisIndiana46256-4697-
Kindred Hair & Skin Center - CARColumbiaMaryland21046-1246-
Revival Research Corporation - Michigan - ClinEdge - PPDSTroyMichigan48084-3536-
Grekin Skin InstituteWarrenMichigan48088-3671-
Henderson Clinical TrialsHendersonNevada89052-5016-
Dartmouth Hitchcock Medical CenterLebanonNew Hampshire03766-1937-
ALLCUTIS Research, LLC.PortsmouthNew Hampshire03801-6822-
Northwell Health Physician Partners Dermatology at Lake Success - BRANY - PPDSNew YorkNew York10003-3314-
Accellacare of CaryCaryNorth Carolina27518-7414-
Bexley Dermatology Research - Probity - PPDSBexleyOhio43209-
Clinical Research Center of the Carolinas, LLCCharlestonSouth Carolina29407-5347-
International Clinical Research-Tennessee LLCMurfreesboroTennessee37130-2450-
Bellaire Dermatology AssociatesBellaireTexas77401-3505-
Progressive Clinical Research PA - San AntonioSan AntonioTexas78213-2250-

Find similar trials in Phoenix, AZ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Saguaro Dermatology Associates, LLC - Probity - PPDS· Phoenix, AZFirst OC Dermatology - Fountain Valley· Fountain Valley, CACenter for Dermatology Clinical Research· Fremont, CAUCLA University of California Los Angeles· Los Angeles, CAUC Davis Dermatology Clinic· Sacramento, CADriven Research LLC· Coral Gables, FL

Related Studies